PharmaCorp Rx Inc.
PCRX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 108.41% | 65.72% | 1.33% | -117.74% | -664.47% |
| Total Depreciation and Amortization | 684.86% | 2,700.61% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -156.52% | 2,890.00% | -- | -- | -- |
| Change in Net Operating Assets | 919.30% | -95.57% | 756.66% | 1,504.18% | -484.43% |
| Cash from Operations | 222.46% | 152.93% | 162.51% | 118.08% | -464.50% |
| Capital Expenditure | -736.00% | -30,898.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1,178.71% | -22,071.67% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,177.20% | -27,012.87% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -280.89% | -1,161.44% | -- | -- | -- |
| Issuance of Common Stock | -88.50% | -61.54% | 352,351.28% | 98,789.21% | 98,789.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.38% | -62.34% | 344,658.62% | 97,139.32% | 97,316.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.08% | -161.93% | 1,827.52% | 2,307.46% | 12,207.96% |